Meeting
2023 ASCO Annual Meeting
Immune related adverse events (irAEs) in patients with solid tumors and advanced chronic kidney disease (CKD) receiving checkpoint inhibitors (CPIs).
Authors
Dalia Kaakour
University of California Irvine Department of Medicine, Orange, CA
Dalia Kaakour , Elham Vosoughi , Brian Warnecke , Omid Yazdanpanah , Arash Rezazadeh , Jennifer Brooke Valerin , Nataliya Mar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2650)
DOI
10.1200/JCO.2023.41.16_suppl.2650
Abstract #
2650
Poster Bd #
492
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A systematic review and meta-analysis of early death (ED) upon immune checkpoint inhibitors (ICI) alone or combined with other non-ICIs treatments as first-line treatment of advanced solid tumors.
First Author: Giuseppe Viscardi
Poster
2022 ASCO Annual Meeting
Dose escalation of davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1).
First Author: Diwakar Davar
Poster
2014 ASCO Annual Meeting
Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors.
First Author: Margaret K. Callahan
Poster
2024 ASCO Annual Meeting
Comprehensive whole genome and transcriptome analysis of patients with advanced solid tumor treated with immune checkpoint inhibitor therapy in the pan-cancer cohorts from the Marathon of Hope Cancer Centres Network Study (MOHCCN).
First Author: Khadjah Alshankati